Company intelligence / Profile preview

Open Innovation Partners

Setagaya-ku, Tokyo, Japanopeninnovationpartners.com ↗

Ownership: Private
Development stage: Other

Overview

Open Innovation Partners, Inc. is a Tokyo-based biotech company focused on developing antibody-drug conjugates targeting c-Met for solid tumors. Its lead asset, TR1801-ADC, is an anti-c-Met antibody-drug conjugate currently in Phase 1 clinical trials for solid tumors. Preclinical data show high potency and activity against c-Met amplified and non-amplified cancers, including overcoming gemcitabine resistance in pancreatic cancer

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateAntibodySmall molecule (as comparator in studies)
Industry: Biotech

Partnerships

Mitsubishi Tanabe Pharmaceutical Corporation

Beyond the preview

Go deeper on Open Innovation Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Open Innovation Partners.

Explore the full profile